Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of BOTOX for facial rhytides (forehead, glabellar, lateral canthal lines)
2014-001815-38Phase 3Completed
- Sponsor
- Allergan
- Start
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of botulinum toxin type A in Rhytidosis facialis, glabellar furrowing, lateral canthal rhytides and 1 more, sponsored by Allergan. Primary endpoint: Investigator-rated forehead line severity at maximum eyebrow elevation. Started Sep 2014; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Rhytidosis facialisglabellar furrowinglateral canthal rhytideswrinkly skin syndrome (WSS)
Beyond the preview
Go deeper on 2014-001815-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001815-38.